Pharmacological treatment of anxiety disorders in children and adolescents: a review for practitioners

被引:24
作者
Patel, Dilip R. [1 ]
Feucht, Cynthia [2 ,3 ,4 ]
Brown, Kelly [1 ]
Ramsay, Jessica [1 ]
机构
[1] Western Michigan Univ, Homer Stryker MD Sch Med, Dept Pediat & Adolescent Med, 1000 Oakland Dr, Kalamazoo, MI 49008 USA
[2] Cynthia Feucht, Kalamazoo, MI USA
[3] Ferris State Univ, Coll Pharm, Big Rapids, MI USA
[4] Borgess Internal Med, Portage, MI USA
关键词
Anxiety disorders; selective serotonin reuptake inhibitors (SSRIs); behavioral activation; serotonin syndrome (SS); bipolar switching; SEROTONIN REUPTAKE INHIBITORS; COGNITIVE-BEHAVIORAL THERAPY; PSYCHOPHARMACOLOGICAL TREATMENT; PEDIATRIC PSYCHOPHARMACOLOGY; RESISTANT DEPRESSION; SAFETY; TADS; EFFICACY; LONG; SSRI;
D O I
10.21037/tp.2017.08.05
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Anxiety disorders are common in children and adolescents with reported prevalence rates between 10% and 30%. A combined approach to treatment has been found to be the most effective for optimal outcomes and is typically comprised of psychotherapy (especially exposure-based cognitive behavior therapy), family and patient education, and use of medication if indicated. In children and adolescents who might benefit from use of medications, selective serotonin reuptake inhibitors (SSRIs) are the drugs of choice. The safety and efficacy of medications other than SSRIs in the treatment of children and adolescents with anxiety disorders are not fully established. Most children and adolescents respond well to treatment with long lasting resolution of symptoms, although, recurrence of the same, or development of a different type of anxiety disorder, is not uncommon. In most children and adolescents, anxiety disorders tend to persist into adulthood requiring long-term treatment planning. This paper reviews the pharmacological agents used in the treatment of anxiety disorders in children and adolescents.
引用
收藏
页码:23 / 35
页数:13
相关论文
共 59 条
[1]  
[Anonymous], 2010, BUSP PACK INS
[2]  
[Anonymous], 2013, DIAGN STAT MAN MENT
[3]  
[Anonymous], LEXI DRUGS R
[4]   Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology [J].
Baldwin, DS ;
Anderson, IM ;
Nutt, DJ ;
Bandelow, B ;
Bond, A ;
Davidson, JRT ;
den Boer, JA ;
Fineberg, NA ;
Knapp, M ;
Scott, J ;
Wittchen, HU .
JOURNAL OF PSYCHOPHARMACOLOGY, 2005, 19 (06) :567-596
[5]  
Barnett S.R., 2003, Pediatric Psychopharmacology, P341
[6]  
Boydston L, 2015, BEHAV PEDIAT, P265
[7]   Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression - The TORDIA randomized controlled trial [J].
Brent, David ;
Emslie, Graham ;
Clarke, Greg ;
Wagner, Karen Dineen ;
Asarnow, Joan Rosenbaum ;
Keller, Marty ;
Vitiello, Benedetto ;
Ritz, Louise ;
Iyengar, Satish ;
Abebe, Kaleab ;
Birmaher, Boris ;
Ryan, Neal ;
Kennard, Betsy ;
Hughes, Carroll ;
DeBar, Lynn ;
McCracken, James ;
Strober, Michael ;
Suddath, Robert ;
Spirito, Anthony ;
Leonard, Henrietta ;
Melhem, Nadine ;
Porta, Giovanna ;
Onorato, Matthew ;
Zelazny, Jamie .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (08) :901-913
[8]  
Buitelaar JK, 2003, PEDIAT PSYCHOHARMACO, P353
[9]  
Chiu S., 2003, Pediatric Psychopharmacology, P274
[10]   Child/Adolescent Anxiety Multimodal Study (CAMS): Rationale, design, and methods [J].
Compton S.N. ;
Walkup J.T. ;
Albano A.M. ;
Piacentini J.C. ;
Birmaher B. ;
Sherrill J.T. ;
Ginsburg G.S. ;
Rynn M.A. ;
McCracken J.T. ;
Waslick B.D. ;
Iyengar S. ;
Kendall P.C. ;
March J.S. .
Child and Adolescent Psychiatry and Mental Health, 4 (1)